BACKGROUND & AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose homeostasis independently of changes in body weight by unknown mechanisms. Melanocortin-4 receptors (MC4R) have weight-independent effects on glucose homeostasis, via autonomic neurons, and also might contribute to weight loss after RYGB. We investigated whether MC4Rs mediate effects of RYGB, such as its weight-independent effects on glucose homeostasis, in mice and humans. METHODS: We studied C57BL/6 mice with diet-induced obesity, MC4R-deficient mice, and mice that re-express MC4R specifically in autonomic neurons after RYGB or sham surgeries. We also sequenced the MC4R locus in patients undergoing RYGB to investigate diabetes resolution in carriers of rare MC4R variants. RESULTS: MC4Rs in autonomic brainstem neurons (including the parasympathetic dorsal motor vagus) mediated improved glucose homeostasis independent of changes in body weight. In contrast, MC4Rs in cholinergic preganglionic motor neurons (sympathetic and parasympathetic) mediated RYGB-induced increased energy expenditure and weight loss. Increased energy expenditure after RYGB is the predominant mechanism of weight loss and confers resistance to weight gain from a high-fat diet, the effects of which are MC4R-dependent. MC4R-dependent effects of RYGB still occurred in mice with Mc4r haplosufficiency, and early stage diabetes resolved at a similar rate in patients with rare variants of MC4R and noncarriers. However, carriers of MC4R (I251L), a rare variant associated with increased weight loss after RYGB and increased basal activity in vitro, were more likely to have early and weight-independent resolution of diabetes than noncarriers, indicating a role for MC4Rs in the effects of RYGB. CONCLUSIONS: MC4Rs in autonomic neurons mediate beneficial effects of RYGB, including weight-independent improved glucose homeostasis, in mice and humans.
BACKGROUND & AIMS: Roux-en-Y gastric bypass (RYGB) improves glucose homeostasis independently of changes in body weight by unknown mechanisms. Melanocortin-4 receptors (MC4R) have weight-independent effects on glucose homeostasis, via autonomic neurons, and also might contribute to weight loss after RYGB. We investigated whether MC4Rs mediate effects of RYGB, such as its weight-independent effects on glucose homeostasis, in mice and humans. METHODS: We studied C57BL/6 mice with diet-induced obesity, MC4R-deficient mice, and mice that re-express MC4R specifically in autonomic neurons after RYGB or sham surgeries. We also sequenced the MC4R locus in patients undergoing RYGB to investigate diabetes resolution in carriers of rare MC4R variants. RESULTS: MC4Rs in autonomic brainstem neurons (including the parasympathetic dorsal motor vagus) mediated improved glucose homeostasis independent of changes in body weight. In contrast, MC4Rs in cholinergic preganglionic motor neurons (sympathetic and parasympathetic) mediated RYGB-induced increased energy expenditure and weight loss. Increased energy expenditure after RYGB is the predominant mechanism of weight loss and confers resistance to weight gain from a high-fat diet, the effects of which are MC4R-dependent. MC4R-dependent effects of RYGB still occurred in mice with Mc4r haplosufficiency, and early stage diabetes resolved at a similar rate in patients with rare variants of MC4R and noncarriers. However, carriers of MC4R (I251L), a rare variant associated with increased weight loss after RYGB and increased basal activity in vitro, were more likely to have early and weight-independent resolution of diabetes than noncarriers, indicating a role for MC4Rs in the effects of RYGB. CONCLUSIONS: MC4Rs in autonomic neurons mediate beneficial effects of RYGB, including weight-independent improved glucose homeostasis, in mice and humans.
Authors: Jari Rossi; Nina Balthasar; David Olson; Michael Scott; Eric Berglund; Charlotte E Lee; Michelle J Choi; Danielle Lauzon; Bradford B Lowell; Joel K Elmquist Journal: Cell Metab Date: 2011-02-02 Impact factor: 27.287
Authors: Miriam Promintzer-Schifferl; Gerhard Prager; Christian Anderwald; Martina Mandl; Harald Esterbauer; Soheila Shakeri-Leidenmühler; Giovanni Pacini; Marietta Stadler; Martin G Bischof; Bernhard Ludvik; Aanton Luger; Michael Krebs Journal: Obesity (Silver Spring) Date: 2011-04-14 Impact factor: 5.002
Authors: Elizabeth A Odstrcil; Juan G Martinez; Carol A Santa Ana; Beiqi Xue; Reva E Schneider; Karen J Steffer; Jack L Porter; John Asplin; Joseph A Kuhn; John S Fordtran Journal: Am J Clin Nutr Date: 2010-08-25 Impact factor: 7.045
Authors: Uyenlinh L Mirshahi; Christopher D Still; Kathryn K Masker; Glenn S Gerhard; David J Carey; Tooraj Mirshahi Journal: J Clin Endocrinol Metab Date: 2011-10-05 Impact factor: 5.958
Authors: John B Buse; Sonia Caprio; William T Cefalu; Antonio Ceriello; Stefano Del Prato; Silvio E Inzucchi; Sue McLaughlin; Gordon L Phillips; R Paul Robertson; Francesco Rubino; Richard Kahn; M Sue Kirkman Journal: Diabetes Care Date: 2009-11 Impact factor: 19.112
Authors: Ivy R Aslan; Guilherme M Campos; Melissa A Calton; Daniel S Evans; Raphael B Merriman; Christian Vaisse Journal: Obes Surg Date: 2011-07 Impact factor: 4.129
Authors: Erica J P Anderson; Masoud Ghamari-Langroudi; Isin Cakir; Michael J Litt; Valerie Chen; Roman E Reggiardo; Glenn L Millhauser; Roger D Cone Journal: J Neuroendocrinol Date: 2019-01-20 Impact factor: 3.627
Authors: Mohamad Mokadem; Juliet F Zechner; Robert F Margolskee; Daniel J Drucker; Vincent Aguirre Journal: Mol Metab Date: 2013-12-11 Impact factor: 7.422
Authors: Z Hao; H Münzberg; K Rezai-Zadeh; M Keenan; D Coulon; H Lu; H-R Berthoud; J Ye Journal: Int J Obes (Lond) Date: 2014-10-28 Impact factor: 5.095